ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • knee pain and osteoarthritis
  • knock-in mice
  • knowledge
  • knowledge and cardiovascular disease risk
  • knowledge and low back pain
  • knowledge and outcomes
  • knowledge and patient engagement
  • knowledge and qualitative
  • knowledge and questionnaires
  • knowledge and rheumatoid arthritis (RA)
  • L-selectin
  • laboratory and imaging evaluation
  • laboratory tests
  • laboratory tests and Diagnostic Tests
  • laboratory tests and multicenter study
  • laboratory tests and musculoskeletal disorders
  • laboratory tests and myositis
  • laboratory tests and obesity
  • laboratory tests and observation
  • laboratory tests and outreach
  • laboratory tests and pain management
  • laboratory tests and quality improvement
  • laboratory tests and registries
  • laboratory tests and rheumatoid arthritis (RA)
  • laboratory tests and skin
  • Laboratory tests and systemic lupus erythematosus (SLE)
  • laboratory tests and thrombosis
  • Laboratory tests and tocilizumab
  • laboratory tests and tuberculosis
  • laboratory tests and ultrasonography
  • laboratory tests and uric acid
  • laboratory tests and vasculitis
  • lactate
  • Lactate Monocarboxylate Transporters
  • lactation
  • lactation and pregnancy
  • LAD
  • Langerhans cell
  • Language
  • language and professionalism
  • large vessel vasculitis
  • large vessel vasculitis and biopsy
  • large vessel vasculitis and CNS Vasculitis
  • large vessel vasculitis and diagnostic imaging
  • large vessel vasculitis and mast cells
  • large vessel vasculitis and meta-analysis
  • large vessel vasculitis and metabolism
  • large vessel vasculitis and positron emission tomography (PET)
  • large vessel vasculitis and quality of life
  • large vessel vasculitis and sacroiliitis
  • large vessel vasculitis and systemic vasculitides
  • large vessel vasculitis and takayasu arteritis
  • large vessel vasculitis and tocilizumab
  • Large vessel vasculitis and ultrasonography
  • large vessel vasculitis and vasculitis
  • Late-Breaking 2015
  • Late-Breaking 2016
  • Late-Breaking 2017
  • Late-Breaking 2018
  • Late-Breaking 2019
  • Late-Breaking 2020
  • Late-Breaking 2021
  • Late-Breaking 2022
  • Late-Breaking 2023
  • Late-Breaking 2024
  • LDH
  • ldl
  • LDL oxidation
  • LDL particle structure
  • Leadership
  • Lean
  • learning collaborative
  • lecture and rheumatoid arthritis (RA)
  • Length of stay
  • Lesions
  • leukemia
  • leukocytes
  • leukocytes and nephritis
  • leukocytes and pharmacology
  • leukocytes and rheumatoid arthritis (RA)
  • leukocytes and synovial fluid
  • leukocytes and systemic lupus erythematosus (SLE)
  • leukocytes and thrombosis
  • leukocytes and transcription factor
  • leukocytopenia,
  • Leukopenia
  • levamisol
  • levamisole-induced autoimmunity
  • level
  • LGBTQ
  • LH ratio
  • Lifestyle
  • ligament and ACR
  • LILRA3
  • LILRA3 and neutrophil extracellular traps
  • limp pain
  • line
  • Lipid
  • lipid profile
  • lipid profile and anti-TNF therapy
  • lipidomics
  • Lipids
  • lipids and cholesterol
  • lipids and fatty acids
  • lipids and Idiopathic Inflammatory Myopathies (IIM)
  • lipids and lupus nephritis
  • lipids and mesenchymal stem cells
  • lipids and metabolism
  • lipids and monocytes
  • lipids and muscle strength
  • lipids and osteoarthritis
  • lipids and outcomes
  • lipids and pediatric rheumatology
  • lipids and PON1
  • lipids and prevention
  • lipids and psoriatic arthritis
  • lipids and regulatory cells
  • lipids and rheumatic disease
  • lipids and rheumatoid arthritis
  • lipids and rheumatoid arthritis (RA)
  • lipids and risk assessment
  • lipids and scleroderma
  • lipids and statins
  • lipids and systemic lupus erythematosus (SLE)
  • Lipids and systemic sclerosis
  • lipids and thrombosis
  • lipids and uric acid
  • lipocalin2
  • lipoprotein and liquid chromatography-mass spectrometry
  • liposomes
  • Literacy
  • livedo
  • livedo reticularis
  • livedo reticularis and mTor
  • Liver
  • liver chemistry
  • Liver chemistry and methotrexate (MTX)
  • liver chemistry and psoriatic arthritis
  • liver disease
  • liver disease and imaging techniques
  • liver disease and randomized trials
  • liver disease and rheumatoid arthritis (RA)
  • liver disease and treatment
  • liver disease and uric acid
  • Liver stiffness
  • LLDAS
  • lncRNA-Dleu2
  • localized scleroderma
  • Long-term
  • long-term extension
  • longitudinal studies
  • longitudinal studies and anti-TNF therapy
  • longitudinal studies and Bone
  • longitudinal studies and clinical trials
  • longitudinal studies and diagnostic criteria
  • longitudinal studies and lupus nephritis
  • longitudinal studies and morbidity and mortality
  • longitudinal studies and obesity
  • longitudinal studies and osteoarthritis
  • longitudinal studies and outcome measures
  • longitudinal studies and outcomes
  • longitudinal studies and pain
  • longitudinal studies and patient outcomes
  • longitudinal studies and pediatric rheumatology
  • longitudinal studies and physical activity
  • longitudinal studies and population studies
  • longitudinal studies and prednisolone
  • longitudinal studies and prognostic factors
  • longitudinal studies and PROMIS
  • longitudinal studies and remission
  • longitudinal studies and renal disease
  • longitudinal studies and rheumatoid arthritis
  • longitudinal studies and rheumatoid arthritis (RA)
  • longitudinal studies and sleep
  • longitudinal studies and systemic lupus erythematosus (SLE)
  • longitudinal studies and systemic sclerosis
  • longitudinal studies and treatment
  • longitudinal studies and ultrasound
  • longitudinal studies and well-being
  • longterm
  • lora
  • Lorecivivint
  • Loss of function
  • Low back pain
  • low back pain and musculoskeletal disorders
  • low back pain and neurologic involvement
  • low back pain and osteoarthritis
  • low back pain and outcomes
  • low back pain and pain
  • low back pain and physical activity
  • low back pain and physical therapy
  • low back pain and quality measures
  • low back pain and questionnaires
  • low back pain and radiology
  • low back pain and randomized trials
  • low back pain and spondylarthritis
  • Low back pain and treatment
  • Low back pain and treatment guidlelines
  • low disease activity
  • low dose CT scans
  • First |
  • « Previous Page
  • 30
  • 31
  • 32
  • 33
  • 34
  • [35]
  • 36
  • 37
  • 38
  • 39
  • 40
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology